Alaproclate (BioDeep_00000600368)
代谢物信息卡片
化学式: C13H18ClNO2 (255.1026)
中文名称: 阿拉普氯酯
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC(C(=O)OC(C)(C)CC1=CC=C(C=C1)Cl)N
InChI: InChI=1S/C13H18ClNO2/c1-9(15)12(16)17-13(2,3)8-10-4-6-11(14)7-5-10/h4-7,9H,8,15H2,1-3H3
描述信息
N - Nervous system > N06 - Psychoanaleptics > N06A - Antidepressants > N06AB - Selective serotonin reuptake inhibitors
D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017367 - Selective Serotonin Reuptake Inhibitors
D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents
D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors
C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent
D049990 - Membrane Transport Modulators
同义名列表
2 个代谢物同义名
数据库引用编号
7 个数据库交叉引用编号
- ChEBI: CHEBI:91544
- KEGGdrug: D02787
- PubChem: 2081
- Metlin: METLIN44412
- DrugBank: DB13233
- ChEMBL: CHEMBL36591
- CAS: 60719-82-6
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- Mark J Henderson, Kathleen A Trychta, Shyh-Ming Yang, Susanne Bäck, Adam Yasgar, Emily S Wires, Carina Danchik, Xiaokang Yan, Hideaki Yano, Lei Shi, Kuo-Jen Wu, Amy Q Wang, Dingyin Tao, Gergely Zahoránszky-Kőhalmi, Xin Hu, Xin Xu, David Maloney, Alexey V Zakharov, Ganesha Rai, Fumihiko Urano, Mikko Airavaara, Oksana Gavrilova, Ajit Jadhav, Yun Wang, Anton Simeonov, Brandon K Harvey. A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
Cell reports.
2021 04; 35(4):109040. doi:
10.1016/j.celrep.2021.109040. [PMID: 33910017] - Tobie D Lee, Olivia W Lee, Kyle R Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, Bethilehem G Tebase, Carleen Klumpp-Thomas, Robert W Robey, Suresh V Ambudkar, Min Shen, Michael M Gottesman, Matthew D Hall. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology.
2019 11; 96(5):629-640. doi:
10.1124/mol.119.115964. [PMID: 31515284] - Gemma Vilahur, Laura Casani, Guiomar Mendieta, Rosa M Lamuela-Raventos, Ramon Estruch, Lina Badimon. Beer elicits vasculoprotective effects through Akt/eNOS activation.
European journal of clinical investigation.
2014 Dec; 44(12):1177-88. doi:
10.1111/eci.12352. [PMID: 25323945] - Gillian W Reierson, Claudio A Mastronardi, Julio Licinio, Ma-Li Wong. Chronic fluoxetine treatment increases daytime melatonin synthesis in the rodent.
Clinical pharmacology : advances and applications.
2009; 1(?):1-6. doi:
10.2147/cpaa.s7157. [PMID: 22291481] - S B Ross. Further studies on the high-affinity binding of 3H-alaproclate to membranes from rat liver and some other tissues.
Pharmacology & toxicology.
1990 Mar; 66(3):170-5. doi:
10.1111/j.1600-0773.1990.tb00727.x. [PMID: 2333272] - O M Phillips, K M Wood, D C Williams. Kinetics of the interaction of sertraline with the human platelet plasma membrane 5-hydroxytryptamine carrier.
European journal of pharmacology.
1988 Feb; 146(2-3):299-306. doi:
10.1016/0014-2999(88)90306-8. [PMID: 3371401] - A M Horn, G Fink. Effects of 5-hydroxytryptamine uptake blockers on the release of LH and prolactin in several different experimental steroid models in the rat.
The Journal of endocrinology.
1985 Mar; 104(3):397-406. doi:
10.1677/joe.0.1040397. [PMID: 3156201] - C Graffner, M Nicklasson, J E Lindgren. Correlations between in vitro dissolution rate and bioavailability of alaproclate tablets.
Journal of pharmacokinetics and biopharmaceutics.
1984 Aug; 12(4):367-80. doi:
10.1007/bf01062663. [PMID: 6527230] - M W Teunissen, A Wahlén, E Vinnars, D D Breimer. Influence of alaproclate on antipyrine metabolite formation in man.
European journal of clinical pharmacology.
1984; 27(4):447-52. doi:
10.1007/bf00549593. [PMID: 6519152] - S J Frost, D Eccleston, E F Marshall, F Hassanyeh. Alaproclate--an open clinical study in depressive illness.
Psychopharmacology.
1984; 83(3):285-7. doi:
10.1007/bf00464796. [PMID: 6433393] - I Bergman, G Bråne, C G Gottfries, K G Jostell, I Karlsson, L Svennerholm. Alaproclate: a pharmacokinetic and biochemical study in patients with dementia of Alzheimer type.
Psychopharmacology.
1983; 80(3):279-83. doi:
10.1007/bf00436170. [PMID: 6412274] - E Syvälahti, P Eneroth, S B Ross. Acute effects of zimelidine and alaproclate, two inhibitors of serotonin uptake, on neuroendocrine function.
Psychiatry research.
1979 Oct; 1(2):111-20. doi:
10.1016/0165-1781(79)90051-9. [PMID: 121774]
